Give all antidepressants, especially since ssris have failed, venlafaxine has tachyphylaxis
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Searching PubMed
treatment-resistant depression
Searching the Web
CANMAT 2023 2024 major depressive disorder pharmacotherapy treatment resistant depression guideline
Reading File
Reading File
Reading File
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064
“Failed SSRIs” and loss of benefit from venlafaxine can justify reassessing the plan, but it does not mean there are no options. First confirm that each trial was adequate, adherence was consistent, and that the diagnosis is unipolar depression rather than bipolar-spectrum illness, substance-related symptoms, untreated sleep disorder, thyroid disease, or another contributor. “Treatment-resistant depression” is often defined as inadequate response to at least two adequate antidepressant trials. The CANMAT 2023 guideline emphasizes individualized switching versus augmentation rather than simply cycling through drugs.
Antidepressant options
Availability and approvals vary by country. This is a practical list of commonly used agents, not a recommendation to self-switch or combine medications.
| Class | Drugs |
|---|---|
| SSRIs | citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline |
| SNRIs | venlafaxine, desvenlafaxine, duloxetine, levomilnacipran; milnacipran in some countries |
| Norepinephrine-dopamine reuptake inhibitor | bupropion |
| Noradrenergic and specific serotonergic antidepressant | mirtazapine; mianserin in some countries |
| Serotonin modulators | vortioxetine, vilazodone |
| Serotonin antagonist/reuptake inhibitors | trazodone, nefazodone |
| Tricyclic antidepressants (TCAs) | amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, trimipramine; maprotiline and lofepramine in some regions |
| Monoamine oxidase inhibitors (MAOIs) | phenelzine, tranylcypromine, isocarboxazid; selegiline transdermal patch; moclobemide in many countries outside the US |
| Other regional agents | agomelatine, reboxetine, tianeptine. Tianeptine is not FDA-approved and has meaningful dependence and overdose concerns. |
| Postpartum-depression specific neurosteroids | brexanolone IV and zuranolone oral, where approved |
Ketamine and intranasal esketamine are not conventional daily oral antidepressants, but are evidence-based specialist options for treatment-resistant depression. Other non-drug treatments include structured psychotherapy, repetitive transcranial magnetic stimulation (rTMS), electroconvulsive therapy (ECT), and sometimes vagus-nerve stimulation.
Especially reasonable topics after SSRI nonresponse and venlafaxine “poop-out”
The best next choice depends on prior side effects, whether venlafaxine gave a partial benefit, anxiety, sleep, appetite/weight change, pain, sexual side effects, blood pressure/heart history, and bipolar risk.
- Bupropion: often considered if low energy, poor concentration, sexual adverse effects on serotonergic drugs, or weight gain are prominent. Can be activating and is generally avoided with seizure disorders or active eating disorders.
- Mirtazapine: often useful when insomnia, low appetite, nausea, or weight loss coexist. Sedation and weight gain can be limiting.
- Duloxetine: reasonable if chronic neuropathic or musculoskeletal pain coexists. Like venlafaxine, it can affect blood pressure and should not be stopped abruptly.
- Vortioxetine: an option after SSRI/SNRI difficulty, often selected where cognitive symptoms or sexual tolerability matter.
- Another SNRI or an SSRI retry: possible, especially if one agent was ineffective but tolerated. However, if several SSRIs truly failed and venlafaxine initially worked then faded, switching to a meaningfully different mechanism is often more appealing.
- Trazodone: more commonly used as a sleep aid at lower doses; antidepressant-level use can be limited by sedation and orthostatic dizziness.
- TCAs, especially nortriptyline or clomipramine in selected contexts: potentially effective but require more caution because of anticholinergic effects, overdose toxicity, orthostasis, and cardiac conduction risks. Baseline ECG consideration is common when risk factors exist.
- MAOIs, particularly phenelzine or tranylcypromine: legitimate later-line options under an experienced psychiatrist. They require strict interaction management and medication washout. Do not combine them with serotonergic antidepressants.
The Maudsley guidance notes that after nonresponse, both switching and augmentation are used; newer guidance finds stronger support for some combinations or adding a second-generation antipsychotic than for repeated switching in certain situations. It also cautions that raising doses often yields modest benefit while worsening tolerability. The Maudsley Prescribing Guidelines in Psychiatry, 15th ed., p. 369.
If venlafaxine helped, then stopped helping
This is often called antidepressant tachyphylaxis or loss of antidepressant benefit. Before assuming it is true pharmacologic tolerance, a prescriber should review:
- Whether there was a full remission versus only partial improvement.
- Missed doses, formulation changes, new medications or supplements, alcohol/cannabis/stimulant use, and withdrawal symptoms between doses.
- New psychosocial stressors, sleep disruption, medical illness, or bipolar-spectrum features.
- Dose, blood pressure, pulse, and side effects.
- Whether the rational next step is dose optimization, augmentation, a cross-taper to a different class, or referral for TRD treatment.
If venlafaxine is being reduced or changed, do not stop it abruptly. It has a relatively high risk of discontinuation symptoms, and switching to an MAOI needs a planned washout to avoid serotonin toxicity.
Augmentation is different from adding another antidepressant
For partial response, a psychiatrist may consider adding rather than replacing treatment. Common evidence-based augmenters include:
- aripiprazole
- brexpiprazole
- quetiapine XR
- lithium
- sometimes liothyronine (T3)
These are not “antidepressants” themselves and have their own monitoring burdens and adverse-effect profiles. A 2025 systematic review and meta-analysis examined multiple treatment regimens in treatment-resistant depression, but choices still need to be individualized rather than based only on a drug ranking.
Important safety points
- Get urgent help now if you have suicidal intent, feel unable to stay safe, develop mania symptoms such as markedly reduced need for sleep plus unusually high energy/impulsivity, or experience confusion, fever, severe agitation, tremor, or diarrhea after serotonergic combinations.
- A history of antidepressant-induced activation, episodic elevated mood, risky behavior, or decreased need for sleep should prompt bipolar screening before further antidepressant escalation.
- If you have palpitations, high blood pressure, fainting, known arrhythmia, or cardiovascular disease, flag this before considering venlafaxine dose changes, bupropion, TCAs, or MAOIs.
A sensible psychiatrist discussion would be: “I have had inadequate benefit from SSRIs and venlafaxine initially worked but lost effect. Can we review whether this is true tachyphylaxis, screen for bipolarity and medical contributors, and compare a class switch such as bupropion, mirtazapine, duloxetine, or vortioxetine versus evidence-based augmentation? If this represents two adequate failures, should we discuss esketamine, rTMS, ECT, a TCA, or an MAOI?”
This is a shared conversation. Sign in to Orris to start your own chat.